Last reviewed · How we verify
IBI308\Cisplatinum\Pemetrexed
IBI308\Cisplatinum\Pemetrexed is a Small molecule drug developed by Innovent Biologics (Suzhou) Co. Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | IBI308\Cisplatinum\Pemetrexed |
|---|---|
| Sponsor | Innovent Biologics (Suzhou) Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation (PHASE1)
- Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure (PHASE3)
- First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IBI308\Cisplatinum\Pemetrexed CI brief — competitive landscape report
- IBI308\Cisplatinum\Pemetrexed updates RSS · CI watch RSS
- Innovent Biologics (Suzhou) Co. Ltd. portfolio CI
Frequently asked questions about IBI308\Cisplatinum\Pemetrexed
What is IBI308\Cisplatinum\Pemetrexed?
IBI308\Cisplatinum\Pemetrexed is a Small molecule drug developed by Innovent Biologics (Suzhou) Co. Ltd..
Who makes IBI308\Cisplatinum\Pemetrexed?
IBI308\Cisplatinum\Pemetrexed is developed by Innovent Biologics (Suzhou) Co. Ltd. (see full Innovent Biologics (Suzhou) Co. Ltd. pipeline at /company/innovent-biologics-suzhou-co-ltd).
What development phase is IBI308\Cisplatinum\Pemetrexed in?
IBI308\Cisplatinum\Pemetrexed is in Phase 1.